Morgan Stanley reports 6% stake in Ventyx Biosciences

Morgan Stanley has filed a Schedule 13G reporting a beneficial ownership stake in Ventyx Biosciences, Inc. common stock.

Rhea-AI Filing Summary

Morgan Stanley has filed a Schedule 13G reporting a beneficial ownership stake in Ventyx Biosciences, Inc. common stock. Morgan Stanley reports aggregate beneficial ownership of 4,289,915 shares, representing 6.0% of the outstanding common stock as of the event date.

The firm reports shared voting and dispositive power over 2,285,401 shares and no sole voting or dispositive power. Morgan Stanley states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Ventyx Biosciences.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake in Ventyx Biosciences does Morgan Stanley (MS) report?

Morgan Stanley reports beneficial ownership of 4,289,915 Ventyx Biosciences common shares, representing 6.0% of the class. This level of ownership requires a Schedule 13G filing, indicating a significant but passive institutional position in the company’s equity.

Is Morgan Stanley seeking control of Ventyx Biosciences (MS)?

Morgan Stanley states the Ventyx Biosciences shares were acquired and are held in the ordinary course of business, not to change or influence control. The filing characterizes the position as passive, consistent with Schedule 13G use by institutional investors.

How much voting power does Morgan Stanley report in Ventyx Biosciences?

Morgan Stanley reports shared voting power over 2,285,401 shares of Ventyx Biosciences common stock and no sole voting power. It also reports shared dispositive power over the same number of shares, reflecting how its reporting units collectively hold and manage the position.

What percentage of Ventyx Biosciences’ stock does Morgan Stanley’s holding represent?

Morgan Stanley’s aggregate beneficial ownership of Ventyx Biosciences common stock is reported as 6.0% of the class. Crossing the 5% threshold triggers a beneficial ownership reporting obligation, which in this case is satisfied through a Schedule 13G filing.

Which Morgan Stanley units are included in this Ventyx Biosciences position?

The filing states it reflects securities beneficially owned, or deemed beneficially owned, by certain “MS Reporting Units” of Morgan Stanley and its affiliates. It clarifies it does not include securities held by other MS units whose ownership is disaggregated under SEC guidance.

What is the event date for Morgan Stanley’s Ventyx Biosciences 13G filing?

The reported date of the event requiring the filing is December 31, 2025. That date marks when Morgan Stanley’s beneficial ownership position in Ventyx Biosciences reached a level or experienced a change necessitating disclosure on Schedule 13G.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/05/2026 - 04:53 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Ventyx Biosciences, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

92332V107

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 92332V107

1

Names of Reporting Persons

Morgan Stanley

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,285,401.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,285,401.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,289,915.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.0 %

12

Type of Reporting Person (See Instructions)

HC, CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Ventyx Biosciences, Inc.
(b)	Address of issuer's principal executive offices: 12790 EL CAMINO REAL, SUITE 200, SAN DIEGO, CA, 92130
Item 2.
(a)	Name of person filing: Morgan Stanley
(b)	Address or principal business office or, if none, residence: 1585 Broadway, New York, NY 10036
(c)	Citizenship: Delaware
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 92332V107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s).
(b)	Percent of class: 6.0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s).
	(ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s).
	(iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s).
	(iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s).
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. * In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Morgan Stanley

Signature:	Chris O'Hara
Name/Title:	Authorized Signatory, Morgan Stanley
Date:	02/05/2026